Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues

Biochemical Pharmacology

Volumn 55, Issue 4, 1998, Pages 465-474

  Rekha, Ganaganur K ^a   Devaraj, Varadahalli R ^a   Sreerama, Lakshmaiah ^a   Lee, Melinda J C ^b   Nagasawa, Herbert T ^b   Sladek, Norman E ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Minnesota   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aldehyde dehydrogenase; Aldophosphamide; Breast cancer; Chlorpropamide analogues; Cyclophosphamide; Drug resistance; Gossypol; Oxazaphosphorines

Indexed keywords

(ACETYLOXY)[(4 CHLOROPHENYL)SULFONYL]CARBAMIC ACID 1,1 DIMETHYLETHYL ESTER; 4 CHLORO N METHOXY N [(PROPYLAMINO)CARBONYL]BENZENESULFONAMIDE; ALDEHYDE DEHYDROGENASE; ALDOPHOSPHAMIDE; CHLORPROPAMIDE; CYCLOPHOSPHAMIDE; GOSSYPOL; MAFOSFAMIDE; OXAZAPHOSPHORINE DERIVATIVE; PHOSPHORAMIDE MUSTARD; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CONTROLLED STUDY; DETOXIFICATION; DRUG RESISTANCE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; TUMOR CELL;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBAMATES; CHLORPROPAMIDE; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; ENZYME INHIBITORS; FEMALE; GASTRIC MUCOSA; HUMANS; KINETICS; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0032519652     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00475-9     Document Type: Article

References (30)

1. Sladek NE, Oxazaphosphorine-specific acquired cellular resistance. In: Drug Resistance in Oncology (Ed. Teicher BA), pp. 375-411. Marcel Dekker, New York, 1993.
2. Sreerama L and Sladek NE, Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol 45: 2487-2505, 1993.
3. Sreerama L and Sladek NE, Overexpression or polycyclic aromatic hydrocarbon-mediated induction of an apparently novel class 3 aldehyde dehydrogenase in human breast adenocarcinoma cells and its relationship to oxazaphosphorine-specific acquired resistance. Adv Exp Med Biol 328: 99-113, 1993.
4. Sreerama L and Sladek NE, Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res 54: 2176-2185, 1994-
5. Sreerama L and Sladek NE, Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide. Drug Metab Dispos 23: 1080-1084, 1995.
6. Bunting KD, Lindahl R and Townsend AJ, Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J Biol Chem 269: 23197-23203, 1994.
7. Rekha GK, Sreerama L and Sladek NE, Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol 48: 1943-1952, 1994.
8. Sladek NE, Sreerama L and Rekha GK, Constitutive and overexpressed human cytosolic class-3 aldehyde dehydrogenases in normal and neoplastic cells/secretions. Adv Exp Med Biol 372: 103-114, 1995.
9. Sreerama L, Rekha GK and Sladek NE, Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance. Biochem Pharmacol 49: 669-675, 1995.
10. Bunting KD and Townsend AJ, Protection by transfected rat or human class 3 aldehyde dehydrogenases against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J Biol Chem 271: 11891-11896, 1996.
11. Rekha GK and Sladek NE, Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Adv Exp Med Biol 414: 133-146, 1997.
12. Devaraj VR, Sreerama L, Lee MJC, Nagasawa HT and Sladek NE, Yeast aldehyde dehydrogenase sensitivity to inhibition by chlorpropamide analogues as an indicator of human aldehyde dehydrogenase sensitivity to these agents. Adv Exp Med Biol 414: 155-169, 1997.
13. Little RG II and Petersen DR, Effect of tolbutamide and chlorpropamide on acetaldehyde metabolism in two inbred strains of mice. Toxicol Appl Pharmacol 80: 206-214, 1985.
14. 1-Alkyl-substituted derivatives of chlorpropamide as inhibitors of aldehyde dehydrogenase. J Med Chem 32: 1335-1340, 1989.
15. 1-Hydroxylated derivatives of chlorpropamide and its analogs as inhibitors of aldehyde dehydrogenase in vivo. J Med Chem 35: 3641-3647, 1992.
16. Lee MJC, Nagasawa HT, Elberling JA and DeMaster EG, Prodrugs of nitroxyl as inhibitors of aldehyde dehydrogenase. J Med Chem 35: 3648-3652, 1992.
17. Feldman RI and Weiner H, Horse liver aldehyde dehydrogenase. II. Kinetics and mechanistic implications of the dehydrogenase and esterase activity. J Biol Chem 247: 267-272, 1972.
18. Sidhu RS and Blair AH, Human liver aldehyde dehydrogenase. Esterase activity. J Biol Chem 250: 7894-7898, 1975.
19. Blatter EE, Abriola DP and Pietruszko R, Aldehyde dehydrogenase. Covalent intermediate in aldehyde dehydrogenation and ester hydrolysis. Biochem J 282: 353-360, 1992.
20. Moreb J, Schweder M, Suresh A and Zucali JR, Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 3: 24-30, 1996.
21. Zheng C-F, Wang TTY and Weiner H, Cloning and expression of the full-length cDNAs encoding human liver class 1 and class 2 aldehyde dehydrogenase. Alcohol Clin Exp Res 17: 828-831, 1993.
22. Sambrook J, Fritsch EF and Maniatis T, Preparation and transformation of competent E. coli. In: Molecular Clonnig. A Laboratory Manual, pp. 1.74-1.84. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.
23. Dockham PA, Lee M-O and Sladek NE, Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 43: 2453-2469, 1992.
24. Chueh S-H, Chang G-G, Chang T-C and Pan F, Involvement of arginine residue in the phosphate binding site of human placental alkaline phosphatase. Int J Biochem 13: 1143-1149, 1981.
25. Lambeir A-M, Loiseau AM, Kuntz DA, Vellieux FM, Michels PAM and Opperdoes FR, The cytosolic and glycosomal glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma brucei. Kinetic properties and comparison with homologous enzymes. Eur J Biochem 198: 429-435, 1991.
26. Wilkinson GN, Statistical estimations in enzyme kinetics. Biochem J 80: 324-332, 1961.
27. +-activated aldehyde dehydrogenase of Saccharomyces cerevisiae. Biochem J 247: 377-384, 1987.
28. Sladek NE, Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In: Anticancer Drugs: Reactive Metabolism and Drug Interactions (Ed. Powis G), pp. 79-156. Pergamon Press, Oxford, 1994.
29. Goedde HW and Agarwal DP, Pharmacogenetics of aldehyde dehydrogenase (ALDH). Pharmacol Ther 45: 345-371, 1990.
30. Nagasawa HT, Kawle SP, Elberling JA, DeMaster EG and Fukuto JM, Prodrugs of nitroxyl as potential aldehyde dehydrogenase inhibitors vis-à-vis vascular smooth muscle relaxants. J Med Chem 38: 1865-1871, 1995.